MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2026020355

Медицинская библиотека · Blood advances · 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Bashey Asad, Logan Brent, Hill LaQuisa, Symons Heather, Farhadfar Nosha, Grunwald Michael R, Pidala Joseph, Dehn Jason G, Brunstein Claudio, Arai Sally, Leifer Eric, He Naya, Shaw Bronwen E, Juckett Mark, Devine Steven, Uberti Joseph, Westervelt Peter, Srour Samer A, Pusic Iskra, Vasu Sumithira, Hayes-Lattin Brandon, Ciurea Stefan O, Horowitz Mary M, Lee Stephanie J, Hogan William J

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

Newer approaches to control alloreactivity may produce similar transplant outcomes using HLA-mismatched donors vs HLA-matched unrelated donors (MUD). However, prospective comparisons are lacking. BMT CTN 1702 used a donor search prognosis score to assign patients to an 8/8 HLA MUD or the center's preference of haploidentical related donors (HAPLO), mismatched unrelated donors (MMUD), or umbilical cord blood (UCB). Outcomes of MUD were compared to HAPLO, MMUD, and UCB transplantation after adjusting for covariates. Patients (n = 1179 [93% adults]) underwent transplantation with MUD (n = 772), HAPLO (n = 254), MMUD (n = 112), and UCB (n = 41) at a median of 3.7, 3.4, 3.9, and 3.8 months from enrollment. Posttransplant cyclophosphamide (PTCy) was used in 23.9%, 83.9%, 65.2%, and 0% of MUD, HAPLO, MMUD, and UCB. In multivariate analyses, compared to MUD, survival was lower for UCB (hazard ratio [HR], 2.65; P< .001) but not statistically different for HAPLO and MMUD (HRs, 1.08 and 1.18, respectively). Relapse risk was not significantly different by donor, but treatment-related mortality (HR, 3.31; P< .001) and disease-free survival (HR, 1.99; P = .002) were inferior for UCB but not different for HAPLO and MMUD than MUD. In patients who received PTCy, HAPLO and MMUD were associated with increased grade 3 or 4 acute graft-versus-host disease (GVHD; HR, 2.39 [P = .017] and 2.53 [P = .038], respectively) and chronic GVHD (HR, 1.71 for both; P = .028 and .080) than MUD, but other outcomes were not different. HAPLO or MMUD may be used to expedite transplantation when finding MUD is unlikely. This study was registered at www.clinicaltrials.gov as NCT03904134.

Для цитирования: Bashey Asad, Logan Brent, Hill LaQuisa, Symons Heather, Farhadfar Nosha, Grunwald Michael R, Pidala Joseph, Dehn Jason G, Brunstein Claudio, Arai Sally, Leifer Eric, He Naya, Shaw Bronwen E, Juckett Mark, Devine Steven, Uberti Joseph, Westervelt Peter, Srour Samer A, Pusic Iskra, Vasu Sumithira, Hayes-Lattin Brandon, Ciurea Stefan O, Horowitz Mary M, Lee Stephanie J, Hogan William J. Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.. Blood advances. 2026. DOI: 10.1182/bloodadvances.2026020355.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.